Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Biomarkers Point to Better Azithromycin Performance in COPD

Key clinical point: When given over 3 months after onset of infectious exacerbation, azithromycin has a greater impact on patients with COPD who have worse biomarkers.

Major finding: In patients treated with azithromycin, hospital readmissions were significantly lower in those with high c-reactive protein (> 50 mg/L, relative risk [RR] = 0.18, 95% CI, 0.05-0.60, P = .005) or low blood eosinophil count (< 300 cells/mcgL, RR = 0.33, 95% CI, 0.17-0.64, P = .001).

Study details: Post-hoc analysis of 3-month, randomized, placebo-controlled, post-hospital-admission study of 301 patients with COPD.

Disclosures: The study is funded by the Flemish Government Agency for Innovation by Science and Technology. Various authors report receiving support from the Flemish Government Agency for Innovation by Science and Technology and consulting fees from Boehringer-Ingelheim and UCB Pharma.

Citation:

Vermeersch K et al. Respir Res. 2019; 20:237.